New drug for recently diagnosed type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new medicine (rezpegaldesleukin) to see if it can help preserve the body's ability to make some insulin in people recently diagnosed with type 1 diabetes. It's for children and adults diagnosed within the past 100 days.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 8 and 45 years old.
- Diagnosed with type 1 diabetes within the last 100 days.
- Must test positive for at least one diabetes-related antibody.
- Must have a certain level of C-peptide (a sign your body still makes some insulin).
- Weigh at least 35 kg (77 lbs) if 18 or older, or be within healthy weight percentiles for your age if under 18.
- Agree to avoid certain vaccines (except flu and COVID-19) during the study and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
This study tests whether a shingles vaccine (Shingrix) combined with a diabetes medication (a GLP-1 agonist) can help preserve your pancreas's ability to make insulin when you've recently been diagnosed with type 1 diabetes. The goal is to slow down the autoimmune attack on your insulin-producing cells.
This trial compares two medicines, teplizumab and ATG, to see if they can delay or prevent type 1 diabetes from progressing to needing insulin. It is for people ages 4 to 35 who have early signs of diabetes (stage 2) and specific autoantibodies.
This early-stage trial tests a combination approach to help your immune system stop attacking insulin-producing cells in newly diagnosed type 1 diabetes. It aims to preserve your body's ability to make insulin and slow disease progression.
This study tests an investigational drug called LY3938577 in healthy people and people with type 1 diabetes. It looks at how the drug affects the body and whether it might help control blood sugar.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.